Phase I results of the randomized evaluation of left ventricular dysfunction (RESOLVD) trial

A new, direct angiotensin-II subtype 1 receptor antagonist, candesartan, was studied in the 60-center, international Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) trial. The trial included two stages: one evaluated candesartan alone and candesartan with the addition of enalapril; the second stage evaluated doses of a beta-blocker, metopolol, which was titrated upward, compared with placebo. Both stages involved …